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ABSTRACT
Introduction: The optimal management for
patients with diabetes and peripheral vascular
disease—intermittent claudication or critical
limb ischemia (CLI)—remains undetermined.
Methods: In a single-center retrospective
analysis, we compared 1- and 5-year
amputation-free survival rates in patients
undergoing angiography subsequently treated
with medical therapy or revascularization.
Results: 78 patients were included, 56 with CLI
(mean age 77 years); 22 with claudication
(mean age 75 years). Of the CLI cohort, 30
patients were medically treated. Their 1-year
amputation-free survival rate was similar to
those treated with revascularization (46.7%
versus 50.0%, respectively). 8 patients in the
claudicant cohort were treated conservatively.
The 1-year amputation-free survival rate was
75.0% for conservative treatment versus 78.6%
in those revascularized. Within the CLI cohort,
in those conservatively treated 20% underwent
major, and 16.7% minor amputations,
compared to 15.4% and 23.1% in those
revascularized. At 5 years in the claudicant
cohort, the amputation-free survival rate was
37.5% with medical treatment, versus 71.4% for
those treated with revascularization. For CLI,
the 5-year amputation-free survival rate was
10% for conservative treatment, versus 26.9%
for revascularization.
Conclusion: We found similar rates of
amputation at 1 year for patients treated
medically or revascularized. However, at 5 years,
the amputation-free survival rate was markedly
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higher in revascularized patients compared to
those medically managed. Our study highlights
the potential role of predicting life expectancy
when considering treatment, with the option of
surgical treatment offered to those in whom
survival is predicted to be longer than 5 years.
However, larger studies with matched cohorts are
now needed to confirm these findings.
Keywords: Amputation; Angiography;
Diabetes; Peripheral vascular disease
INTRODUCTION
The International Diabetes Federation estimates
more than 387 million people worldwide were
affected by diabetes in 2014, with this number
predicted to rise to 592 million by 2035 [1].
Diabetes-related foot disease, in particular foot
ulcers, remains one of the main complications
caused by a combination of peripheral
neuropathy, infection, and peripheral arterial
disease (PAD) [2]. Recent data have shown that
diabetes is second only to smoking as a cause of
PAD [3]. More than one million people a year
undergo amputation of the lower limb, with
85% of cases precipitated by a foot ulcer [4]. In
England, an estimated £639 million to £662
million (0.6–0.7% of the total National Health
Service budget) is spent on the treatment of
diabetic foot ulceration and amputation [5].
Aside from the economic burden, there are
often considerable social and psychological
impacts associated with the diagnosis of
diabetes [6].
Infection and PAD form the two major
indications for lower limb amputation in
diabetes [7, 8]. The Framingham Heart Study
(ClinicalTrials.gov identifier, NCT00005121)
showed one-fifth of patients with symptomatic
PAD suffered also from diabetes, although the
actual prevalence is likely to be higher as most
cases of PAD are asymptomatic [9]. The most
frequently observed presentation of
symptomatic PAD is intermittent claudication;
described as a reproducible pain or cramp of the
lower limb on walking, which is then relieved
by rest. At the other end of the spectrum, a
minority of patients will present with features
of critical limb ischemia (CLI): rest pain, tissue
loss with ulceration and gangrene. Of note, in
patients with PAD associated with diabetes, the
diseased vessel is often distal, (femoro-popliteal
and tibial), whereas PAD secondary to other risk
factors (e.g., smoking, hypercholesterolemia),
generally occurs in more proximal
(aorto–ilio-femoral) vessels [6]. PAD, which
progresses faster in the population with
diabetes, has been shown in large
observational studies to complicate up to half
of all diabetic foot ulcer cases, and is an
independent risk factor for amputation [6,
10–12]. The prognosis of patients with a
diabetic foot ulcer and PAD is poor, with a
50% dying at 5 years, and at 2 years following a
major amputation [13].
The Inter-Society Consensus for the
Management of Peripheral Arterial Disease
(TASC II) in 2007 and the United Kingdom
(UK) National Institute for Health and Clinical
Excellence (NICE) in 2012 have published
guidelines on the diagnosis and management
of PAD [14, 15]. However, evidence-based
guidelines for the management of patients
with diabetes presenting with PAD is lacking.
In 2011, in the UK NICE produced guidance on
the management of diabetic foot problems in
hospitalized patients but were unable to provide
recommendations on the optimal time for
either revascularization or orthopedic
interventions to prevent amputation due to a
lack of evidence [16]. A review by Brownrigg
et al. focusing on the evidence-based strategies
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for diabetic foot ulceration advised best medical
therapy (wound care with debridement,
treatment of infection, off-loading with a
6-week period of observation) for patients with
diabetes and mild PAD with an ankle-brachial
index of C0.6 [17].
In large ulcers with possible infection, early
vascular intervention may be required due to
poor outcomes with conservative therapy.
Revascularization is also advised for those
patients where PAD is contributing to poor
wound healing, with the exception of very frail
patients or those with an unsalvageable foot [17].
A systematic review in 2012 demonstrated
improved rates of limb salvage in patients with
diabetes with foot ulcers undergoing
revascularization compared to those treated
medically; however, the authors concluded that
there were insufficient data to recommend one
form of revascularization over another [18].
In summary, due to the relatively scarcity of
good quality evidence, there remains
uncertainty as to the best way to manage
patients with diabetes who have a degree of
PAD. Our aim was to present a descriptive
analysis of the clinical outcome of
revascularization versus medical management
in patients with claudication and CLI at our
own regional multidisciplinary diabetes foot
clinic, as measured by their amputation-free
survival rate at 1 and 5 years. In particular, to
examine how our patient results compare to
other similar studies.
MATERIALS AND METHODS
We performed a retrospective analysis of all of
our patients attending the tertiary specialist
diabetes vascular foot clinic with diabetes who
underwent an angiogram of the lower limb
during the 24-month period from January 2009
to December 2010. We retrospectively reviewed
their medical notes to record their foot disease
history, disease presentation, co-morbidities
and medication, intervention, and 1-year
clinical outcome. For those patients that were
alive and without minor or major amputation
at 1 year, we analyzed their disease outcome in
terms of amputation-fee survival again at 5-year
follow-up.
Disease presentation was recorded as
claudication or CLI (ulcer, gangrene or rest
pain). Intervention was defined as conservative
medical management, or revascularization
(which included angioplasty, profundoplasty,
embolectomy, endarterectomy, or bypass). For
medical management, we recorded the reason
for this conservative approach as follows: unfit
for surgery; patient refusal; joint decision by
clinician and patient to treat conservatively; no
option for or failed revascularization; and
symptom resolution by the time of the
procedure. The clinical outcome in the same
lower limb was recorded as ‘no amputation’,
‘minor amputation’ (trans-metatarsal, forefoot
or digits), ‘major amputation’ (above or below
knee) or ‘death’ (from whatever cause). We
calculated the 1- and 5-year amputation-free
survival rate to compare the outcome of
medical versus surgical intervention in the
treatment of claudication and CLI.
Compliance with Ethics Guidelines
Due to the retrospective, anonymous nature of
the study, the Norfolk and Norwich University
Hospitals NHS Foundation Trust ethics
committee classed this as a service
improvement exercise and ethical approval
was deemed to not be necessary.
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RESULTS
A total of 78 patients with diabetes from our
specialist clinic underwent lower limb
angiography at our institution between
January 2009 and December 2010. 56 patients
had presentations of CLI, while 22 patients had
claudication symptoms only. Table 1 shows the
baseline characteristics of the two cohorts.
Figure 1a, b illustrates the 1-year outcome of
the two cohorts, along with the reason for
conservative management and form of
revascularization performed. The 8 patients
who were treated conservatively in the
claudicant cohort included one patient who
presented 6 months after their initial
presentation of claudication with CLI,
resulting in one major above knee amputation.
Comparison of baseline micro- and
macro-vascular complications of the two
treatment arms showed the following results.
Within the claudicant group, the mean
Estimated Glomerular Filtration Rate (eGFR)
was slightly lower at 56.6 mL/min/1.73 m2 in
the no revascularization group, and 65.1 mL/
min/1.73 m2 in the revascularization group.
Conversely, for patients with critical ischemia,
the mean eGFR was higher in the medically
treated cohort (58.4 versus 53.8 mL/min/
1.73 m2).
Amongst the claudicants, for the 8 patients
treated medically, 4 had cardiovascular disease
[3 with stable angina only, and 1 with previous
non ST-Segment elevation myocardial
infarction (NSTEMI)/ST segment elevation
myocardial infarction (STEMI)], and no patient
had previous transient ischemic attack (TIA) or
stroke. In comparison, within the 14 patients
that underwent revascularization, a higher
proportion of patients had cardiovascular
disease (7 patients with stable angina only, 6
with STEMI/NSTEMI), and TIA/stroke (4
patients) complications.
For critical ischemia, amongst the 30
patients treated conservatively, 21 had
cardiovascular complications (12 stable angina
only, 9 STEMI/NSTEMI) and 4 had TIA/stroke.
For those 26 patients treated surgically, a
slightly higher proportion of patients had
cardiovascular (11 stable angina only and 11
NSTEMI/STEMI) and TIA/stroke (8 patients)
complications.
With regards to risk factors for arterial
disease, similar proportions of claudicant
patients were ex- or current smokers within
the medical and surgical treatment groups
(62.5% versus 57.1%, respectively). For critical
ischemia, there was a higher proportion of ex-
or current smokers for those patients treated
surgically (69.2% versus 36.7%).
Analysis of diabetes related risk factors shows
the mean glycated hemoglobin (HbA1c) was
lower for patients treated medically in the
claudicant cohort (54 versus 62 mmol/mol),
but higher in critical ischemia patients treated
medically (64 versus 56 mmol/mol). In this
study, the majority of patients had Type 2
diabetes, with only 4 patients with Type 1. The
proportion of patients on insulin therapy
compared to diet or tablet alone was similar
for both medically and surgically treated patient
cohorts in the claudicant arm (25% versus
28.6%, respectively), but was markedly higher
for those patients treated medically within the
critical ischemia arm (53.3% versus 15.4%).
Review of baseline surgical status showed
42.9% of patients in the claudicant group
treated with revascularization had prior
surgery compared to 37.5% of patients treated
conservatively. For critical ischemia, patients in
the revascularization cohort had slightly higher
rates of previous surgical intervention (50%
484 Diabetes Ther (2015) 6:481–493
Table 1 Clinical characteristics of patients treated by conservative and revascularization in the claudication and critical
limb ischemia cohorts









Age (mean, years) 72.1 75.9 77.9 76.3
M/F 6/2 13/1 20/10 12/14
Diabetes
Type1/type 2 1/7 0/14 3/27 0/26
Type 2 management
Diet 1 2 3 10
Tablet 4 8 8 12
Insulin 2 4 16 4
Mean HbA1c (mmol/mol) 54 62 64 56
Mean eGFR (mL/min/1.73 m2) 56.6 65.1 58.4 53.8
Previous surgical intervention
Y/N
3/5 6/8 13/17 13/13
Risk factors
Stable angina 3 7 12 11
Previous STEMI/NSTEMI 1 6 9 11
Previous TIA/stroke 0 4 4 8
Ex or current smoker 5 8 11 18
Concurrent medications
Aspirin 8 12 18 17
Statin 5 12 21 17
Fibrate 0 0 0 2







Location unavailable 1 3
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versus 43.3%). Prior surgery included both
amputation and vascular intervention. Data of
individual procedural types were unfortunately
not collected.
In the claudicant group, the 1-year
amputation-free survival rate for medical
therapy was 75% versus 78.6% in those
patients treated with revascularization. The
5-year amputation-free survival was 37.5% for
conservative treatment, versus 71.4% for those
treated with revascularization.
For the CLI cohort, 46.7% of patients had a
1-year amputation-free survival rate in the
cohort of patients treated conservatively
compared to 50% in the patients treated with
revasculariZation. Of the 56 patients presenting
with CLI, 15.4% underwent a major amputation
at 1-year follow-up in the revascularization
group compared to 20% in the conservative
arm. For minor amputations, the rate was 23.1%
for revascularization versus 16.7% for
conservative therapy. The 5-year
amputation-free survival rate was 10% in the
conservative arm compared to 26.9% for those
treated with revascularization.
Finally, within the revascularization cohort,
a distinction can be made between
endovascular procedures and bypass surgery.
Subgroup analysis shows the endovascular route
results in a 1-year amputation-free survival rate
of 75% versus 100% for bypass surgery in
claudicants. At 5 years, however, the
amputation-free survival rate was higher at
33.3% for the endovascular procedures, versus
0% for bypass. For critical ischemia, the
outcomes are more comparable, with 1 year
amputation-free survival rates of 52.9% for
endovascular procedures and 44.4% for bypass
surgery. Five-year amputation-free survival rates
were 17.6% for endovascular versus 22% for
bypass procedures.
The data we present here are descriptive
only, with no attempts at statistical analysis due
to the small sample size and retrospective
nature of the study, which made any further
comparisons between the cohorts unreliable.
DISCUSSION
In this study, we demonstrate revascularization
to be a more effective treatment for claudicants
and patients with CLI, with approximately
double the amputation-free survival rate at
5 years. However, our study has also
demonstrated similar amputation outcomes at
1-year follow-up for patients treated with either
medical or revascularization therapy for both
presentations of claudication and CLI.
Our results at 1 year would suggest that
conservative management of CLI and
claudication is as effective as surgical
intervention in terms of limb preservation. For
patients, this would mean a similar clinical
outcome without the risks and complications of
Table 1 continued









Rest pain 2 8
HbA1c glycated hemoglobin, eGFR estimated glomerular ﬁltration rate, STEMI ST segment elevation myocardial infarction,
NSTEMI non ST-Segment elevation myocardial infarction, TIA transient ischemic attack, ACE angiotensin-converting
enzyme, ARB angiotensin 2 receptor blockers
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Fig. 1 a, b One-year clinical outcome of patients treated by medical versus revascularization for presentations of critical
limb ischemia and claudication
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surgery, and a financial benefit for the health
system. Our data are in contrast to previous
work that has shown better rates of limb salvage
for patients undergoing vascular intervention
[18, 19]. The results of these reviews also reflect
the current UK national and international
guidelines for the management of PAD—
although it must be acknowledged that these
guidelines are not specific to diabetes [14]. The
TASC II and 2012 NICE guidelines on
intermittent claudication recommend initial
conservative treatment with a supervised
exercise program and modification of risk
factors, with a plan for angioplasty and
possible bypass surgery if these measures prove
to be unsuccessful [14, 15]. For CLI, NICE
recommends revascularization therapy over
conservative measures, as assessed by a
dedicated vascular multidisciplinary team [15].
TASC II is also in favor of revascularization over
conservative measures for CLI if the patient is fit
for surgery [14]. In addition, the guideline
recommends best medical management or
amputation if there is intolerable pain or
spreading infection [14]. Nevertheless, whilst
the findings of the current study are in contrast
to these guidelines, they are in accordance with
2 other studies that show that best medical
management for the diabetic foot at 1 year is
associated with similar outcomes as
revascularization [20, 21]. Elgzyri et al.
conducted a prospective study of 602 patients
with diabetes who all presented to a
multidisciplinary foot center with foot ulcers,
but who were deemed to be unsuitable for
revascularization [20]. These authors
demonstrated limb salvage rates of 56% and
77%, respectively, at 1 year, with significant
healing with conservative measures or with
minor amputation alone [20, 21].
In terms of the nature of amputation, i.e.
major versus minor, within the CLI cohort, we
demonstrate a modest reduction in major
amputation rates in the revascularization
cohort compared to conservative therapy at
1 year. However, this is at the expense of a
higher rate of minor amputations in this group.
Whether this outcome is acceptable is
dependent on the needs of the individual
patient, the quality of the prosthesis and the
success of rehabilitation. A large prospective
study examining the long-term prognosis of
189 patients with diabetes undergoing major
and minor amputations showed 93% of patients
retuned to living independently following a
minor amputation compared to 61% having a
major amputation. More patients with minor
amputations also regained their original
walking capacity in comparison to patients
after major amputations [22]. Although
revascularization lowers the rate of major
amputations in patients presenting with CLI, a
longer follow-up period may be necessary to
ascertain the significance of the higher rate of
minor amputations, as many of these cases may
eventually progress to major amputation. A
recent study to demonstrate this phenomena
in patients with diabetes showed an average
interval from minor to major amputation of
591.0 and 559.6 days for mild-to-moderate and
severe PAD, respectively. Thus, a longer
follow-up of our patients beyond the 365 days
may show a similar outcome for those who
underwent a minor amputation [23].
A number of factors may account for the
differences at 1 year between our results and the
findings of other published data in terms of
clinical outcome between revascularization and
conservative therapy. Our sample size was
relatively small; thus between-group
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comparisons were more difficult and we make
no statement about statistical significance
between the groups. Compared to other
similar published studies, many of which
follow up patients for many years, or until
wound healing or death, our 1-year follow-up
period is relatively short. Indeed for a number of
our patients, minor or major amputations
occurred at 13 or 14 months following their
initial angiogram, but these were not included
due to the 12-month follow-up criteria. In
addition, our analysis included the results of
78 patients at our regional diabetes foot center.
However, similar studies examining the
outcomes of diabetes and peripheral vascular
disease, for example the EURODIALE study and
the BASIL trials (National Institute of Health
Research HTA—96/05/01), are large multicenter
trials with data for hundreds of patients. Thus, if
our study were to be extended to involve larger
populations with matched cohorts, the
amputation-free survival rate of medical versus
revascularization at 1 year may be different to
the current values.
In addition, larger multicenter trials would
also allow subgroup analysis of data. Of interest,
the distinction between endovascular
procedures and more invasive bypass surgery is
a clinically significant one: the endovascular
route is less invasive, can be performed under
local anesthesia as a day case, and can be
performed more than once. Results of
subgroup analysis for critical ischemia in this
study show comparable one- and 5-year
amputation-free survival rates for the two
revascularization routes; however, small
cohorts make further analysis of data unreliable.
Within the CLI cohort, we recorded also the
location of ulcer and gangrene for patients
treated by conservative and revascularization
(Table 1). Location was recorded as forefoot
(hallux and toes), mid-foot (to include
metatarsals, dorsal and plantar surfaces of the
foot), heel, ankle, leg or location unavailable.
The majority of such lesions occurred on the
forefoot of both treatment arms. The very small
numbers of ulcers and gangrene occurring
elsewhere in the lower limb make any further
analysis of the relationship between location
and rate of amputation unreliable.
In addition, as a retrospective study, the data
collected are limited to the information already
available from previously documented events,
rather than prospectively collecting
information specific to this study question.
Prospective data collection may provide a
more detailed account of disease presentation,
co-morbidities, and medication history of the
patient.
Recent studies show the outcome of a
diabetic foot ulcer is not only affected by the
severity of ischemia, but also by the extent of
tissue loss, the presence of infection, and
certain co-morbidities of the patient [24]. For
example, there is evidence that the presence of
stroke and the microvascular complications of
diabetes are strongly associated with lower limb
amputation. However, the rate of amputation
in patients with and without coronary artery
disease and/or myocardial infarction was not
significantly different [25, 26]. In our study,
despite aggressive revascularization therapy, the
1-year amputation-free survival rate is similar
for claudicant patients treated by both medical
and surgical approaches. The absence of
superiority of revascularization may be partly
explained by the differing patient
characteristics of the two treatment arms. For
example, there is a higher prevalence of
previous TIA/stroke (4 versus 0 patients), and a
higher mean HbA1c (62 versus 54 mmol/mol),
within the cohort treated with revascularization
compared to those treated medically. As
discussed above, could patients with a history
Diabetes Ther (2015) 6:481–493 489
of cerebrovascular disease and poorly controlled
diabetes, and therefore, a greater likelihood of
microvascular complications, be more likely to
progress to amputation regardless of aggressive
therapy?
In a similar fashion, patients with chronic
kidney disease (eGFR \60 ml/min) and those
treated with renal dialysis have a higher rate of
below- and above-knee amputations in
comparison with diabetic patients without
renal disease [27]. In our study, within the
group of patients presenting with CLI, the mean
eGFR is lower for those patients treated
surgically in comparison to those treated
medically (53.8 versus 58.4 mL/min/1.73 m2).
In our study, the degree of tissue loss, presence
of infection, and severity of ischemia were not
recorded. The use of randomization or
matching techniques to take into account
these confounding factors is difficult to
perform in our current study population due
to the relatively small sample size. Nevertheless,
patients with diabetes who have certain
co-morbidities associated with higher rates of
amputation may warrant an earlier and more
intensive treatment approach for long-term
limb preservation. In a similar fashion, all
patients, whether treated with conservative or
surgical measures, would benefit from tight
glycemic and blood pressure control to reduce
both the microvascular complications and thus
rates of lower extremity amputation.
A comment needs to be made about the
apparent lack of use of adjuvant therapies
(Table 1), in particular statins, in our cohort.
Many of these individuals also had some
underlying wound infections. Our
standardized antibiotic protocol advocates the
use of clarithromycin or fucidin at times [28].
The use of either of these drugs necessitates the
stopping of statin therapy to avoid potential
interaction and subsequent rhabdomyolysis.
Finally, the success of revascularization
therapy for lower limb PAD was traditionally
reported in terms of arterial patency and limb
salvage. However, there remain questions as to
if these are accurate predictors of functional
outcome for the patient—in particular
improved mobility and independence. Taylor
et al. in 2006 examined both the technical
outcome of reconstruction patency and limb
salvage, as well as the functional outcome of
ambulation and maintenance of independent
living, for 841 patients with CLI at a University
Medical Center [29]. Results of that study
suggested some patients—in particular those
with dementia—may have had a technically
satisfactory outcome, including limb salvage,
but may not have experienced any improved
functional outcome. That group of patients
overall performed worse than those patients
who lost their limbs, in terms of survival,
ambulation, and independent living [29].
Thus, despite achieving arterial patency and
long-term limb salvage, some patients may still
suffer from functional disabilities that result in
both a reduced sense of well-being for the
individual, as well as a significant financial
burden on the healthcare system. In this
context, despite similar amputation-free
survival rates for our two cohorts at 1 year, it
is necessary also to assess how this compares
with the functional outcome for our patients in
terms of maintenance of mobility and quality of
life. Our data are in agreement with recent
guidance from the International Working
Group of the Diabetic Foot who recommends
that ‘‘revascularization should be avoided in
patients in whom, from the patient perspective;
the risk–benefit ratio for the probability of
success is unfavorable’’ [30]. In line with the
above, it would be interesting to assess length
and frequency of hospital admission for the
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patients in this study as these factors can also
have a significant impact on quality of life.
We acknowledge that our data have their
limitations. It is retrospective in nature, a
relatively small sample size and a relatively
short follow-up period. We have also not
described in detail the nature of the severity of
the PAD. Our study is also similar to previous
work because our subjects lack matching
between the 2 groups. In addition, there is an
absence of correlation between the clinical
endpoints and functional outcomes. It is
imperative to take into consideration
significant baseline patient characteristics such
as glycaemic control, renal function, and other
micro/macro-vascular risk factors, when
comparing medical versus revascularization
therapy on amputation-free survival outcomes.
Unfortunately due to small sample size and
retrospective nature of our study, matching of
the treatment arms was not performed. Future
studies taking into account such confounding
factors will enable more reliable conclusions to
be drawn.
Thus, our data suggest similar outcomes for
medically and surgically managed patients with
PAD at 1 year and superior outcomes for surgery
at 5-year follow-up; however, firm conclusions
cannot be drawn at present due significant
patient differences of the two treatment arms.
Baseline renal function, diabetic control, and
vascular complications should also be taken
into account when predicting for patient
survival. Nevertheless, a risk stratification
model should be implemented because
patients with certain risk factors strongly
associated with lower limb amputation, for
example, microvascular complications of
diabetes, may still be best managed with a
more intensive approach.
CONCLUSION
In summary, our study suggests that best
medical management for PAD in diabetes may
be as effective as surgical intervention at 1-year
follow-up in terms of limb salvage for patients
with claudication and CLI. We show that
patients presenting with CLI treated
conservatively at our diabetic foot center do
not necessarily progress rapidly to amputation
at 1 year. In contrast, at 5 years, patients treated
surgically have a much higher amputation-free
survival rate for both types of PAD. Although
limiting surgery to those patients predicted to
have a longer life expectancy may be feasible,
with reductions in the costs of surgery and
avoidance of potentially unnecessary surgical
risks, larger studies are now needed to confirm
this.
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